Saturday, October 3, 2026

EUR/JPY Went Down By Over 1% In The Last 10 Sessions

EUR/JPY Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 1.67% for the last 10 sessions. At 05:06 EST on Friday, 19 July, EUR/JPY (EURJPY) is $171.10.

EUR/JPY's yearly highs and lows, it's 15.773% up from its 52-week low and 2.458% down from its 52-week high.

Volatility

EUR/JPY's last week, last month's, and last quarter's current intraday variation average was a negative 0.08%, a positive 0.07%, and a positive 0.37%, respectively.

EUR/JPY's highest amplitude of average volatility was 0.44% (last week), 0.33% (last month), and 0.37% (last quarter), respectively.

Previous days news about EUR/JPY (EURJPY)

  • Eur/jpy price analysis: the first upside target emerges above 172.50. According to FXStreet on Wednesday, 17 July, "The EUR/JPY cross weakens near 172.45 on Wednesday during the early European session. ", " According to the 4-hour chart, the bearish outlook of EUR/JPY remains intact as the cross holds below the key 100-period Exponential Moving Averages (EMA)."
  • Eur/jpy price analysis: appreciates to near 171.00; next barrier at 23.6% fibonacci level. According to FXStreet on Thursday, 18 July, "The EUR/JPY cross is likely to test the immediate resistance at the psychological level of 171.00, followed by the 23.6% Fibonacci retracement level at 171.29, positioned between the coordinates of 175.43 and 170.01 levels.", "Moreover, the 14-day Relative Strength Index (RSI), a momentum indicator, is below the 50 level, suggesting a confirmation of a bearish bias for the EUR/JPY cross."
  • Eur/jpy steadies as ecb’s hold rates, traders eye lagarde’s presser. According to FXStreet on Thursday, 18 July, "The EUR/JPY remains at familiar levels after the European Central Bank decided to keep interest rates unchanged, with its deposit rate at 3.75% as expected, and would stick to its meeting-by-meeting approach, failing to provide an interest rate path. ", "However, if EUR/JPY stays above 171.00, that could pave the way to test July's 17 high of 172.83. "

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com